Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|June 2, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-06-07-2016
- Volume 11
- Issue 6
FUJIFILM Opens New Laboratory in North Carolina
Author(s)Pharmaceutical Technology Editors
The company opened its 62,000 square foot facility, called the BioProcess Innovation Center, in Triangle Park, NC.
Advertisement
FUJIFILM Diosynth Biotechnologies completed construction on a new three-story, 62,000-square-foot facility in Research Triangle Park, NC. A ribbon cutting ceremony was held on May 9, 2016, the company said in a
Source:
Articles in this issue
over 10 years ago
Slow Serialization Efforts May Delay Business Benefitsover 10 years ago
Scientific Approach Ensures Accurate Weighing Resultsover 10 years ago
Ensuring Biologic API Uniformityover 10 years ago
Biomanufacturing Outsourcing Budgets Grow, Slowlyover 10 years ago
Novasep Starts Kilogram-Scale Batch Production at US Facilityover 10 years ago
Catalent Opens Korean Sales Officeover 10 years ago
Juniper Pharma Services Expands Topicals Capacityover 10 years ago
ED-XRF Spectrometers Offer Rapid Elemental Analysisover 10 years ago
Raman Microscope Measures Uneven Surfacesover 10 years ago
Particle Analyzer Based on Light ScatteringAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement